¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"common acute lymphoblastic leukemia antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • complete antigen
    ¿ÏÀüÇ׿ø
  • conjugated antigen
    Á¢ÇÕÇ׿ø, °áÇÕÇ׿ø
  • carcinoembryonic antigen
    ¾Ï¹è¾ÆÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • diphasic antigen
    ÀÌ»óÇ׿ø
  • early antigen
    ÃʱâÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    ±äÅÐÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ±ºÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • Thy-1 antigen
    Thy-1Ç׿ø
  • U antigen
    U Ç׿ø
  • V antigen
    V Ç׿ø
  • Vi antigen
    ViÇ׿ø.
  • Wright Antigen
    ¶óÀÌÆ®Ç׿ø
  • a antigen
    A Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø, ±ÙÁ¢Ç׿ø(ÐÎïÈù÷ê«).
  • analysis, antigen
    Ç׿øºÐ¼®
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • adult T Cell leukemia virus
    ¼ºÀÎ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult T cell leukemia virus (HTLV)
    ¼ºÀÎT¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult t-cell leukemia/lymphoma
    ¼º¼÷ T-¼¼Æ÷ ¹éÇ÷º´/¸²ÇÁÁ¾(à÷âÙ¡­á¬øà ÛÜúìÜ»/¡­ðþ)
  • aleukemic leukemia =aleukocythemic l.
    ¹«¹éÇ÷º´¼º ¹éÇ÷º´(ÙíÛÜúìÜ»àõÛÜúìÜ»).
  • aleukemic leukemia =aleukocythemic l.
    ¹«¹éÇ÷º´¼º ¹éÇ÷º´(ËÎËÑÌ´ËÓËÛËÑÌ´ËÓ).
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¼º ¹éÇ÷º´(ÍéâÐÙíû¡à÷àõÛÜúìÜ»).
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¼º ¹éÇ÷º´(Ë­ËàËÎÌ´ËÛËÛËÑÌ´ËÓ).
  • avian leukemia virus
    Á¶·ù¹éÇ÷º´¹ÙÀÌ·¯½º
  • avian leukemia virus
    Á¶·ù ¹éÇ÷º´¹ÙÀÌ·¯½º
  • basophilic leukemia
    È£¿°±â¼º ¹éÇ÷º´(?ËÑÌ´ËÓ).
  • basophilic leukemia
    È£¿°±â±¸¼º ¹éÇ÷º´(¡­ÛÜúìÜ»).
  • bovine leukemia virus
    ¼Ò¹éÇ÷º´¹ÙÀÌ·¯½º
  • chronic granulocytic leukemia =CGL
    ¸¸¼º°ú¸³±¸(¼º)¹éÇ÷º´(??ËöË´ËÛËÑ Ì´ËÓ).
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸(¼º)¹éÇ÷º´(¡­Ï¹àõÛÜúìÜ»).
  • chronic lymphocytic leukemia
    ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
MLS mean lifespan; median life span; median longitudinal section; microphthalmia-linear skin defects [sy...
MLV Moloney leukemia virus; multilaminar vesicle; murine leukemia virus
MML Moloney murine leukemia; monomethyllysine; myelomonocytic leukemia
ALL Acute Lymphocytic Leukemia
  ÇüÅÂÇÐÀû ºÐ·ù
    L1; Small, Homogenous(...
AcLV avian acute leukemia virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
CC Common Carotid
CCA Common Carotid Arteries
CCA Common Carotid Artery
CORBA Common Object Request Broker Architecture
CPN Common Peroneal Nerve
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute dacryocystitis
    ±Þ¼º ´«¹°ÁÖ¸Ó´Ï ¿°Áõ, ±Þ¼º ´©³¶¿°
    ºñ·ç°üÀÇ »ó, ÇÏ´Ü ¾çÀÚÀÇ ÀϺΠ¶Ç´Â ¿ÏÀüÆó»ö¿¡ ÀÇÇØ »ç°­Çü¼ºÀÌ »ý±èÀ¸·Î½á ÀÏÀ¸Å²´Ù. ¸¸¼º´©³¶¿°¿¡ ÀÇÇØ Áö¼ÓÀûÀ¸·Î ¿°ÁõÀÌ ÀÖÀ¸¸é Á¾Ã¢ÀÌ »ý±â°í ÀÌ ºÎÀ§¿¡¼­ Æó»öÀÌ »ý±ä´Ù. ÀÌ »ç°­³»¿¡¼­ ¿°Áõº´¼Ò´Â ºÎÇ®¾î ¿Ã¶ó¼­ ÁÖÀ§¸¦ ¾Ð¹ÚÇÑ´Ù. ±Þ¼º´©³¶¿°À» ±ÙÄ¡½ÃŰ·Á¸é ´©³¶ÀûÃâ¼ú, ¶Ç´Â ºñ·ç¹®ÇÕ¼úÀ» ÇàÇÑ´Ù. ±â¿°±ÕÀ¸·Î¼­ Æ÷µµ±¸±Õ, Æó·Å±¸±ÕÀÌ ÀÖ°í ºñ·ç°üÀÇ »óÇÏ´Ü Æó»öÀ» ÀÏÀ¸Å°´Â ¿Ü»ó ¶Ç Çü¼ÍºÎÀüÁõ, ÇØºÎÇÐÀû ÀÌ»óµµ ¿øÀÎÀÌ µÈ´Ù.
  • acute delirium
    ±Þ¼º Çê¼Ò¸®, ±Þ¼º ¼¶¸Á
  • acute demyelinating disease
    ±Þ¼º Å»¼öÃʼº Áúȯ
  • acute dermatitis
    ±Þ¼º ÇǺο°
  • acute dilutional hyponatremia
    ±Þ¼º Èñ¼®¼º Àú³ªÆ®·ýÇ÷Áõ
  • acute disseminated encephalitis
    ±Þ¼º ÆÄÁ¾¼º ³ú¿°
  • acute diverticulitis
    ±Þ¼º °Ô½Ç¿°
  • acute eczema
    ±Þ¼º ½ÀÁø
    µ¿ÀǾî=eczema acutum.
  • acute endocarditis
    ±Þ¼º ½É³»¸·¿°
    ±Þ¼ºÀÇ °æ°ú¸¦ ÃëÇÏ´Â ½É³»¸·¿°, Æó·Å, ¼ö¸·¿°, »ê¿å¿­, ±× ¹ÛÀÇ °¨¿°ÁõÀ¸·Î ÀÕµû¶ó ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹´Ù. ¿øÀαÕÀ¸·Î¼­´Â Æ÷µµ»ó ±¸±Õ, ¼ö¸·¿°±Õ, Æó·Å±Õ µîÀÌ ÀÖ´Ù. ½É³»¸·ÀÇ º´º¯Àº °íµµÀÌ°í ÆÇ¸·Á¶Á÷ÀÇ ÆÄ±«°¡ ½ÉÇÏ¸é ÆÇ¸·ÀÇ Ãµ°ø, °Ç»öÀÇ ´Ü¿­À» °¡Á®¿À´Â ¼öµµ ÀÖ´Ù. ÀÓ»óÀûÀ¸·Î´Â ¹ß¿­, ½ÉÀâÀ½, Ç÷ħġ ÃËÁø, ºñÁ¾ µîÀ» º¸°Ô µÈ´Ù. Ç÷¾× ¹è¾çÀÌ Áø´Ü¿¡ Áß¿äÇÏ´Ù. Ä¡·á´Â Æä´Ï½Ç¸° ±× ¹ÛÀÇ Ç×»ýÁ¦¸¦ Åõ¿©ÇÑ´Ù.
  • acute epidemic leukoencephalitis
    ±Þ¼º À¯Ç༺ ¹é ³ú¿°, ±Þ¼º À¯Ç༺ ¹éÁú ³ú¿°
  • acute epididymoorchitis
    ±Þ¼º °íȯ ºÎ°íȯ¿°
  • acute erythematous atrophic candidosis
    ±Þ¼º È«¹Ý¼º À§Ã༺ ĵµð´ÙÁõ
  • acute erythremia
    ±Þ¼º ÀûÇ÷º´
  • acute exacerbation
    ±Þ¼º Áõ¿À
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ÀÇ ¸»±â¿¡ ±Þ¼º ¹éÇ÷º´ »óÅ·Π¾ÇÈ­ÇÏ´Â °Í. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Å¹ÝÀÌ °ñ¼ö¾Æ±¸
  • acute exposure
    ±Þ¼º ÇÇÆø
    ¹æ»ç¼± °Ç°­°ü¸®Çлó »ç¿ëµÇ´Â ¿ë¾îÀÌ°í ¹æ»ç¼± »ç°í µî, ºñ±³Àû ªÀº ½Ã°£¿¡ °íü°¡ ÇÇÆøÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. Á÷¾÷ÀûÀ¸·Î ¾Æ¹«·¡µµ ÇÇÇÒ ¼ö ¾ø´Â ÇÇÆøÀ̳ª ½ºÆ®·ÐƬÀÇ »À¿¡ ´ëÇÑ Ä§Âø µî Àå¹Ý°¨±âÀÇ ¹æ»ç¼± µ¿À§¿ø¼Ò°¡ ¸ö ¾È¿¡ µé¾î°£ °æ¿ìÀÇ ÇÇÆøÀ» ¸¸¼º ÇÇÆøÀ̶ó°í ¸»Çϴµ¥ ´ëÇØ¼­ À̰°ÀÌ ¸»ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
acute kidney transplant rejection <radiology> Findings on ultrasound: globular enlargment of the kidney, swelling and hypoechogenicity of the medullary pyramids, indistinct cortico-medullary junction, foci in the renal cortex
(12 Dec 1998)
acute leukaemia <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months.
See: acute lymphoblastic leukaemia, acute myeloid leukaemia.
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lobar nephrosis A severe but localised bacterial infection of the renal parenchyma that may produce a mass effect simulating a renal abscess.
(05 Mar 2000)
acute lower GI haemorrhage <gastroenterology> Typical presentation: Sudden onset of brisk rectal bleeding without blood in gastric aspirate Diagnostic considerations: diverticulosis, angiodysplasia, ischemic colitis, inflammatory bowel disease (rarely), polyps are usually present, carcinoma causing a chronic bleed, haemorrhoids.
(12 Dec 1998)
acute lymphocytic leukaemia <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis
(12 Dec 1998)
acute malaria A form of malaria that may be intermittent or remittent, consisting of a chill accompanied and followed by fever with its attendant general symptoms, and terminating in a sweating stage; the paroxysms, caused by release of merozoites from infected cells, recur every 48 hours in tertian (vivax or ovale) malaria, every 72 hours in quartan (malariae) malaria, and at indefinite but frequent intervals, usually about 48 hours, in malignant tertian (falciparum) malaria.
(05 Mar 2000)
acute mania An excited mental state seen in a bipolar (manic-depressive) disorder characterised by hyperactivity, talkativeness, flight of ideas, pressured speech, grandiosity, and, occasionally, grandiose delusions.
See: mania, manic-depressive.
Synonym: acute mania.
(05 Mar 2000)
acute miliary tuberculosis A rapidly fatal disease due to the general dissemination of tubercle bacilli in the blood, resulting in the formation of miliary tubercles in various organs and tissues, and producing symptoms of profound toxaemia.
Synonym: acute miliary tuberculosis, disseminated tuberculosis.
(05 Mar 2000)
acute monocytic leukaemia <haematology> The most common translocation in this disorder of poorly differentiated monocytic cells involves chromosome region 11q in a large percentage of cases.
The translocation involves a cellular oncogene, c-ets which is mapped to the 11q23-24 region. The most common translocations reported are t(6;11), t(9;11), t(11;17) and t(11;19), of which t(9;11) (p21-22;q23) is by far the most frequently detected and implicated in acute myeloid leukaemia. The cells express CD14 surface antigen, which is diagnostic of monocytic cells.
Acronym: AML
Classification: FAB M5
(07 Apr 1998)
acute mountain sickness <chest medicine> A condition that results from prolonged exposure to high altitude.
Symptoms include a continuous dry cough, shortness of breath, poor exercise tolerance, dizziness, headache, sleep difficulty, anorexia, confusion, fatigue and a rapid pulse.
Treatment includes the immediate movement to a lower altitude. Prophylaxis has been accomplished successfully with the use of acetazolamide (Diamox).
(27 Sep 1997)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute necrotizing encephalitis An acute form of encephalitis, characterised by destruction of brain parenchyme.
(05 Mar 2000)
acute necrotizing haemorrhagic encephalomyelitis A fulminating demyelinating disorder of the central nervous system that affects mainly children and young adults. Almost always preceded by a respiratory infection, characterised by the abrupt onset of fever, headache, confusion, and nuchal rigidity, soon followed by focal seizures, hemiplegia, or quadriplegia, brainstem findings, and coma; the CSF shows evidence of an inflammatory process; due to the massive destruction of the white matter of one or both hemispheres, often accompanied by similar destruction of the white matter of the brainstem and cerebellar peduncles; of unknown aetiology.
Synonym: acute haemorrhagic leukoencephalitis, acute necrotizing haemorrhagic leukoencephalitis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á